Health Care • Biotechnology: Pharmaceutical Preparations
$106.20 ▲ +1.63
(+1.56%)
MKT CAP: $180.95B • VOL: 8.44M
52W L $82 52W H $132
ABT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $44.33B | $41.95B | $40.11B |
| YoY Revenue Growth % | +5.7% | +4.6% | — |
| Gross Profit | $25.01B | $23.24B | — |
| Gross Margin % | 56.4% | 55.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $8.05B | $6.83B | $6.48B |
| Operating Margin % | 18.2% | 16.3% | 16.2% |
| Net Income (GAAP) | $6.52B | $13.40B | $5.72B |
| EBITDA (Normalized) | $9.79B | $8.59B | $7.92B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $9.57B | $8.56B | $7.26B |
| Capital Expenditures (CapEx) | $2.17B | $2.21B | $1.80B |
| Free Cash Flow (FCF) | $7.39B | $6.35B | $5.46B |
| FCF Margin % | 16.7% | 15.1% | 13.6% |
| Return on Invested Capital (ROIC %) | 11.9% | 10.2% | 8.5% |
| Cash & Short-Term Equivalents | $8.52B | $7.62B | — |
| Total Debt (Short + Long Term) | $9.90B | $12.63B | $23.29B |
| Total Stockholders' Equity | $52.13B | $47.66B | $47.77B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABT.